Chemomab Therapeutics Ltd. CMMB
biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with
high unmet needs. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed
CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe
and life-threatening fibrotic and inflammatory diseases.
CMMB is a depositary receipt: one CMMB stands for 20 shares of this company, per the cover page of its latest 10-K. The market cap and the multiples above are stated per receipt; the statements below, including EPS, are as filed and are per underlying share.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $2.3M | $2.5M | $4.4M | $5.1M | $3.3M | — | — | — | — | — |
| R&D | $5.8M | $11.3M | $18.4M | $17.0M | $6.3M | $4.7M | $13.3M | $7.5M | — | — |
| SG&A | $3.7M | $3.4M | $7.1M | $11.6M | $6.0M | $1.3M | $6.2M | $5.5M | — | — |
| Total operating expenses | $9.6M | $14.7M | $25.5M | $28.5M | $12.4M | $6.0M | $22.9M | $13.0M | — | — |
| Operating income | -$112.0M | -$103.0M | — | — | — | — | — | -$13.0M | -$9.4M | -$4.6M |
| Pre-tax income | -$9.0M | -$13.9M | -$24.2M | -$28.2M | -$12.5M | $6.0M | $27.1M | $13.5M | — | — |
| Income tax | $0 | $0 | $0 | $534.0K | $0 | $0 | $0 | $306.0K | — | — |
| Net income | -$9.0M | -$13.9M | -$24.2M | -$27.6M | -$12.5M | -$6.0M | -$27.1M | -$13.8M | -$9.8M | -$4.7M |
| EPS, basic | 0.02 | 0.04 | 0.10 | 0.12 | 0.06 | — | — | — | — | — |
| EPS, diluted | 0.02 | 0.04 | 0.10 | 0.12 | 0.06 | 0.04 | 0.79 | 1.09 | — | — |
| Shares, diluted (wtd. avg.) | 510.2M | 359.0M | 235.0M | 227.6M | 207.5M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.6M | $6.1M | $9.4M | $13.6M | $15.2M | $11.7M | $12.3M | $7.6M | $1.5M | — |
| Receivables | — | — | — | — | — | — | $408.0K | $3.4M | — | — |
| Total current assets | $13.4M | $16.0M | $20.9M | $41.7M | $62.7M | $11.8M | $18.2M | $10.9M | — | — |
| Property, plant and equipment | $176.0K | $250.0K | $303.0K | $367.0K | $357.0K | $152.0K | $158.0K | $385.0K | — | — |
| Total assets | $13.8M | $17.0M | $22.2M | $43.1M | $64.4M | $12.5M | $19.8M | $12.8M | $2.1M | — |
| Total current liabilities | $1.5M | $3.2M | $4.8M | $6.7M | $2.6M | $1.3M | $4.1M | $2.7M | — | — |
| Total liabilities | $1.5M | $3.4M | $5.2M | $6.8M | $2.9M | $1.7M | $4.8M | $3.0M | — | — |
| Retained earnings | -$111.6M | -$102.6M | -$88.7M | -$63.8M | -$36.2M | -$23.7M | -$105.4M | -$78.3M | — | — |
| Total equity | $12.3M | $13.5M | $17.0M | $36.2M | $61.5M | $10.8M | $12.4M | $9.8M | -$609.0K | $3.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.1M | -$15.4M | -$23.6M | -$20.4M | -$12.4M | -$5.2M | -$16.5M | -$14.2M | — | — |
| Depreciation and amortisation | $70.0K | $53.0K | $67.0K | $58.0K | $34.0K | $24.0K | $281.0K | $66.0K | — | — |
| Stock-based compensation | $623.0K | $617.0K | $1.5M | $3.2M | $2.0M | $130.0K | $1.2M | $1.9M | — | — |
| Capital expenditure | $3.0K | $0 | $3.0K | $68.0K | $239.0K | $38.0K | $95.0K | $213.0K | — | — |
| Investing cash flow | $5.4M | $2.3M | $15.9M | $19.5M | -$45.2M | -$62.0K | -$95.0K | -$213.0K | — | — |
| Financing cash flow | $7.2M | $9.9M | $3.5M | -$808.0K | $61.1M | $4.8M | $26.6M | $20.6M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001178913-26-001593.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$4.7M | -$9.8M | -$13.8M | -$27.1M | -$6.0M | -$12.5M | -$27.6M | -$24.2M | -$13.9M | -$9.0M |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |